- No Results -

*profile not configured

Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a
GJ Knott, BF Cress, JJ Liu, BW Thornton, RJ Lew, B Al-Shayeb, ...
eLife 8, e49110 2019
Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors
TP Huang, KT Zhao, SM Miller, NM Gaudelli, BL Oakes, C Fellmann, ...
Nature biotechnology 37 (6), 626 2019
Controlling CRISPR-Cas9 with ligand-activated and ligand-deactivated sgRNAs
K Kundert, JE Lucas, KE Watters, C Fellmann, AH Ng, BM Heineike, ...
Nature Communications 10 (1), 2127 2019
MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival
CS Lee, LC Lee, TL Yuan, S Chakka, C Fellmann, SW Lowe, NJ Caplen, ...
Proceedings of the National Academy of Sciences 116 (10), 4508-4517 2019
CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification
BL Oakes, C Fellmann, H Rishi, KL Taylor, SM Ren, DC Nadler, R Yokoo, ...
Cell 176 (1-2), 254-267. e16 2019
Systematic discovery of natural CRISPR-Cas12a inhibitors
KE Watters, C Fellmann, HB Bai, SM Ren, JA Doudna
Science 362 (6411), 236-239 2018
Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner
A Mancini, A Xavier-Magalhães, WS Woods, KT Nguyen, AM Amen, ...
Cancer Cell 34 (3), 513-528. e8 2018
Extension of the crRNA enhances Cpf1 gene editing in vitro and in vivo
HM Park, H Liu, J Wu, A Chong, V Mackley, C Fellmann, A Rao, F Jiang, ...
Nature Communications 9 (1), 3313 2018
Differential Effector Engagement by Oncogenic KRAS
TL Yuan, A Amzallag, R Bagni, M Yi, S Afghani, W Burgan, N Fer, ...
Cell Reports 22 (7), 1889-1902 2018
Prediction of potent shRNAs with a sequential classification algorithm
R Pelossof, L Fairchild, CH Huang, C Widmer, VT Sreedharan, N Sinha, ...
Nature Biotechnology 35 (4), 350-353 2017
Cornerstones of CRISPR-Cas in drug discovery and therapy
C Fellmann, BG Gowen, PC Lin, JA Doudna, JE Corn
Nature Reviews Drug Discovery 16 (2), 89-100 2017
Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch
BL Oakes, DC Nadler, A Flamholz, C Fellmann, BT Staahl, JA Doudna, ...
Nature biotechnology 34 (6), 646-651 2016
MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2
DG Nowak, H Cho, T Herzka, K Watrud, DV DeMarco, VMY Wang, ...
Cancer discovery 5 (6), 636-651 2015
C Fellmann
US Patent 20,150,018,539 2015
A Computational Algorithm to Predict shRNA Potency
SRV Knott, AR Maceli, N Erard, K Chang, K Marran, X Zhou, A Gordon, ...
Molecular cell 56 (6), 796-807 2014
High throughput methods for functionally determining RNA interference efficiency
C Fellmann, SW Lowe, GJ Hannon, JE Zuber
US Patent 8,901,288 2014
Development of siRNA payloads to target KRAS-mutant cancer
TL Yuan, C Fellmann, CS Lee, CD Ritchie, V Thapar, LC Lee, DJ Hsu, ...
Cancer discovery 4 (10), 1182-1197 2014
Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma
F Robert, W Roman, A Bramoullé, C Fellmann, A Roulston, C Shustik, ...
Proceedings of the National Academy of Sciences 111 (37), 13421-13426 2014
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors
P Lito, A Saborowski, J Yue, M Solomon, E Joseph, S Gadal, ...
Cancer Cell 25 (5), 697-710 2014
Stable RNA interference rules for silencing
C Fellmann, SW Lowe
Nature cell biology 16 (1), 10-18 2014
An optimized microRNA backbone for effective single-copy RNAi
C Fellmann, T Hoffmann, V Sridhar, B Hopfgartner, M Muhar, M Roth, ...
Cell reports 5 (6), 1704-1713 2013
A pipeline for the generation of shRNA transgenic mice
LE Dow, PK Premsrirut, J Zuber, C Fellmann, K McJunkin, C Miething, ...
Nature protocols 7 (2), 374-393 2012
Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy
X Tan, ZJ Lu, G Gao, Q Xu, L Hu, C Fellmann, MZ Li, H Qu, SW Lowe, ...
Proceedings of the National Academy of Sciences 109 (3), 869-874 2012
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance
J Zuber, AR Rappaport, W Luo, E Wang, C Chen, AV Vaseva, J Shi, ...
Genes & development 25 (15), 1628-1640 2011
Functional identification of optimized RNAi triggers using a massively parallel sensor assay
C Fellmann, J Zuber, K McJunkin, K Chang, CD Malone, RA Dickins, Q Xu, ...
Molecular cell 41 (6), 733-746 2011
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi
J Zuber, K McJunkin, C Fellmann, LE Dow, MJ Taylor, GJ Hannon, ...
Nature biotechnology 29 (1), 79-83 2011
HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase
A Sendoel, I Kohler, C Fellmann, SW Lowe, MO Hengartner
Nature 465 (7298), 577-583 2010